Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO.

Paul Chaplin

Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014. He has led the development of the company’s smallpox and mpox vaccine. Under his leadership, Bavarian Nordic has grown from a small research-based company with a single government customer to a large vaccine manufacturer with strong commercial operations in key markets, the company describes.

“I am leaving Bavarian Nordic with great pride. I have truly enjoyed the experiences and professional challenges over nearly three decades and have had the privilege of leading many talented colleagues towards a shared mission of improving and saving lives. We have achieved a lot and created a strong foundation for the future of the company. My family wants to relocate back to Australia, but I remain fully committed to the company for the remainder of the year to allow for a stable transition to its next CEO,” says Paul Chaplin.